acromegaly/iiveldus

Link salvestatakse lõikelauale

Artiklid Kliinilistes uuringutesPatendid

Valige sortimise tüüp

Leht 1 alates 40 tulemused

Spontaneous remission of acromegaly after infarctive apoplexy with a possible relation to MRI and diabetes mellitus.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

OBJECTIVE Pituitary apoplexy is a rare clinical syndrome associated with rapid enlargement of a pituitary mass. We report the initial presentation, subsequent course and outcome of an acromegalic patient who developed spontaneous remission following pituitary apoplexy with pathologic findings of

Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The long term effectiveness and tolerance of terguride, a new ergot derivative, as initial therapy were evaluated in 20 patients with pathological hyperprolactinemia (PHP; group A) and 7 patients with acromegaly. We also studied 10 patients with PHP whose treatment was changed from bromocriptine or

Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Pasireotide (SOM-230) is a small somatostatin (SST) analog that is being developed by Novartis Pharma AG for the potential treatment of acromegaly, Cushing's disease and neuroendocrine tumors; the compound is currently in phase III clinical trials for Cushing's disease. Pasireotide exhibits high

Complete surgical resolution of bilateral total opthalmoplegia without visual field defect in an acromegalic patient presented with pituitary apoplexy.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Pituitary apoplexy (PA), which is one of the most serious life-threatening complications of pituitary adenoma, is characterized by abrupt onset of headache, nausea, vomiting, visual disturbances and oculomotor paresis. Combination of oculomotor cranial nerve paralysis with normal visual fields is

Pituitary apoplexy probably due to TRH and GnRH stimulation tests in a patient with acromegaly.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Pituitary apoplexy is the most serious and life-threatening complication of pituitary adenomas. Most of the cases occur spontaneously but it may occur also after a number of events such as the pituitary stimulation tests. We report a case of acromegaly due to a giant pituitary adenoma in which

Spontaneous cerebrospinal fluid rhinorrhea as the initial presentation of growth hormone-secreting pituitary adenoma.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Patients with acromegaly usually present with characteristic clinical features or comorbidities associated with excess insulinlike growth factor 1 (IGF-1)/growth hormone (GH) or may come to medical attention secondary to mass effects causing visual field distortions. Herein, we report a case of

Adverse events associated with somatostatin analogs in acromegaly.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

BACKGROUND In patients with acromegaly, somatostatin analogs (SSA) represent the first choice medical treatment. The long-acting SSA have been found to be effective in controlling growth hormone and IGF-I levels in a high percentage of patients, resulting in an improvement in the quality of life;

[Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Plasma GH levels were studied following acute administration of 2.5 mg of bromocriptine (CB 154) in 12 acromegalic patients. In 9 responders, reduction of GH levels was obvious 2 to 4 hours after bromocriptine administration and the lowest values were achieved between 5 and 8 hours following drug

[Results of treatment for acromegaly with long-acting bromocriptine (Parlodel LAR)].

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Long-acting bromocriptine (Parlodel LAR) was used for treatment of 25 patients with acromegaly during the period of 3 to 24 months. Even after the first intramuscular injection of 50 milligrams of the drug a decrease in growth hormone (GH) concentration by at least 50% of the initial values was

The effect of a new ergoline derivative, CU 32-085, in the treatment of acromegaly. A controlled study.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The effect of a new dopamine agonist, CU 32-085 (8 alpha-amino-ergoline), on pituitary function in acromegaly was evaluated by a controlled, single blind study of 12 acromegalics. The study included a single dose placebo/drug (0.5 mg CU 32-085) trial and a long-term crossover trial with 3 month

Spontaneous remission of acromegaly: apoplexy mimicking meningitis or meningitis as a cause of apoplexy?

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Pituitary apoplexy is a rare but potentially life-threatening clinical syndrome characterized by ischemic infarction or hemorrhage into a pituitary tumor. The diagnosis of pituitary tumor apoplexy is frequently complicated because of the nonspecific nature of its signs and symptoms, which can mimic

Depot-bromocriptine treatment for prolactinomas and acromegaly.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Fifteen patients with hyperprolactinaemia and pituitary macroadenomas (5 patients), microadenomas (6 patients), or acromegaly (4 patients) were given a single intramuscular injection of 50 mg bromocriptine bound to polylactic acid microspheres, depot-bromocriptine. None of the patients had any

Effect of different dopaminergic agents in the treatment of acromegaly.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

Medical treatment of acromegaly with dopamine agonists possesses 2 main advantages: the oral administration and the low costs. In this study, we reported on the results of chronic treatments with quinagolide (CV 205-502), cabergoline (CAB) and long-acting depot preparation of bromocriptine (BRC-LAR)

Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

The effectiveness and side effects of a newly developed, repeatable depot-bromocriptine preparation, (Parlodel LAR, depot-bromocriptine), were studied in 7 acromegalic patients. A dose of 100 mg was injected at intervals of 28 days for 4 months, followed by 200 mg for 2 months. GH profiles (14 h)

Medical management of acromegaly--what and when?

Ainult registreeritud kasutajad saavad artikleid tõlkida

Logi sisse

GH and IGF-I levels are elevated in patients with acromegaly. At the time of diagnosis patients present with macroadenomas with a high surgical failure rate or microadenomas. Administration of octreotide (100 micrograms, three times daily) suppressed GH secretion during 8 h to < 5 micrograms/l in

Eelmine
1
2
3
Järgmine

Liitu meie
facebooki lehega

Herbal & Natural Medicine

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

Töötab 55 keeles
Taimsed ravimid, mida toetab teadus
Maitsetaimede äratundmine pildi järgi
Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
Lugege oma otsinguga seotud teaduspublikatsioone
Otsige ravimtaimi nende mõju järgi
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel